FDAsafety guidance72% confidence
New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (liver cancer) as Alnylam Pharmaceuticals.
Regulatory Analysis
Discover potential signals of serious risks and new safety information identified by the FDA's Adverse Event Monitoring System (AEMS). Learn how the FDA monitors and evaluates drugs for safety concerns, providing important updates on adverse events to protect public health.
Supporting Context
- Therapeutic area
- Oncology · Hepatocellular Carcinoma
- Sub-indication
- Liver Cancer
Related signal: Alnylam's ALN-BCAT Study in Hepatocellular Carcinoma Evaluates Safety and Efficacy